Member Info for Alpha-dog

I’ve just sent sky news a link to our P3 long Covid data on the back of their story suggesting metformin was the only P3 drug to show long Covid benefit.

https://academic.oup.com/ofid/article/9/Supplement_2/ofac492.1879/6903622

Not that long ago any news, even a fraction of this magnitude would send H2 stocks much higher.

H2 is happening- more certainly, more urgently and to greater extent than thought 12-18 months ago, yet share prices languish. Patience needed.

Https://twitter.com/1goodtern/status/1662523057322307587?s=46&t=lUUs8mZ3DzN0LONpU_7P4w

This is as an interesting observation on current uk data.

Neither.

The reliable part is hospital testing, ITU admissions and scripts for antivirals.

Community testing has long since been abandoned and sentinel community testing also abandoned. In the uk collection of hospital, ICU data also suspended.

A local hospital closed this week due to Covid outbreaks but no central data collected any more.

Arguably UK is taking Trump approach….if it’s not measured it doesn’t exist.

Https://www.health.gov.au/health-alerts/covid-19/case-numbers-and-statistics?language=und

Looking at Australia Covid charts it’s pretty clear fairly large numbers of people are still getting pretty ill. Look particularly at hospital cases and scripts for antivirals for indicators of what’s going on. The hospitalisations lag scripts. ITU admissions haven’t jumped yet but they may well follow. This wave hasn’t peaked yet but has been going on for longer than other waves. Total numbers may be close to previous waves though peak not as high yet.

This may be one of the last reliable metrics left to track Covid.

They definitely have skin in the game and are currently on fairly big paper losses. I think last purchase may have been circa £10.

My take on this is that issues are geopolitical. That’s no comfort though.

I re-read the original RNS. I was thinking there might be a way for Bosch to progress without Weichai but I can’t see it. Weichai are in both JVs.

I’m hoping there is a plan B. If there is it’s well under wraps but I suppose it would be until it is announced unless of course to put pressure on Weichai.

Thanks Tennents.

This may be pretty big news. I’m not absolutely certain on the technical side but the 30MEP bar is a step up in pressure from the 20 MEP bar they produced previously. The 30MEP process underpins the larger 10MW modules that form the basis of the 200MW RWE contract.

Today plug shot up 14% on basis of 3 orders signed based on their current 5MW system- what they describe as the « largest in the world ». If todays ITM announcement signals that they are well on the way to delivering 10MW modules then this is huge. As per my previous post if ITM is entering a new phase of starting to deliver at scale then it’s hugely undervalued IMO.

Https://theenergyst.com/itm-power-raises-250-million-to-boost-electrolyser-output/

This is a historic article but illustrates how much ITM partners valued the company and technology.

While there have been serious supply side and performance issues this last 12 months Linde clearly haven’t written off ITM- they placed a 200MW order.

Worth noting also that competition haven’t excelled on the delivery side yet- plug delivered 66MW in first 3 months 2023.

Much of the Linde cash raise is still there and company currently valued at little more than cash in hand. In addition today has seen 14bn committed by Japanese companies to consortia that ITM have previously done business with. Bottom line is huge potential upside here if ITM under Schultz can deliver at scale.

https://www.world-nuclear-news.org/Articles/Coalition-applies-for-US-hydrogen-hub-funding
No guarantees this would involve ITM but interesting

https://www.independent.co.uk/news/ap-michigan-gretchen-whitmer-norwegian-detroit-b2331833.html?amp
Nel and GM collaboration appears to be bearing fruit. I’m hoping DS is correct that ITM will be firing on all cylinders and won’t miss out on big opportunities.
I’m liking how focussed he is on the larger electrolysers. I

https://www.independent.co.uk/news/ap-michigan-gretchen-whitmer-norwegian-detroit-b2331833.html?amp
Seems to be a pretty huge vote of confidence from GM and a deepening of US relationship.

That is a sizeable hydrogen investment and commitment.

I’m with you Dudio. The emphasis here was on focussed investigator led studies (plural). Usually in investigator led studies the pharma company will provide the investigational agent. The studies are en on a much lower cost than pharma sponsored studies. They do tend to rely on non-pharma funding eg MRC. Downside is timescale and ownership of results: we saw that with ACTIV2 when positive results took a long time to be fully released to SNG.
The suggestion was that these should start in q2/3 23 which would imply that they were pretty much agreed in principle but perhaps going through or about to go through ethics/R&D at the sites.
I’m not convinced we’ll see any shift in SP until these start to be confirmed in the next 3-6 months hopefully. I get the feeling that some may be very focussed eg immunosuppressed, possibly those with interferon deficiency. That may allow registration with the bigger SPRINTER and other P2s used as really good evidence of safety- although results non-significant statistically they central estimates were towards benefit in pretty much every aspect measured.
Traders may well have some ups and downs between now and then but I think investors can take heart. I don’t think a big fund raise for further P3 likely.

https://www.lancs.live/news/uk-world-news/arcturus-covid-latest-ukhsa-reports-26758201?int_source=amp_continue_reading&int_medium=amp&int_campaign=continue_reading_button#amp-readmore-target
5 desths out of 105 Arcturus sequences. Clearly this can’t be taken as a « fatality rate » as cases sequenced not representative but difficult to see this as anything other than potentially worrying.

https://www.h2-view.com/story/usnc-hyundai-sk-es-target-nuclear-hydrogen-production-in-south-korea/
This type of deal is Ceres core market for SOEC.
From memory the JVs didn’t cover SOEC. It would be helpful if next partner wasn’t so caught up in geopolitical issues.

Thank you DS for taking the time to answer these investor queries on this board. I’m sure I speak for all the investors who frequent this board.

https://www.biorxiv.org/content/10.1101/2023.04.12.536671v1
This link was re-tweeted by Eric Fiegel Ding- eminent Harvard epidemiologist who posts on Covid. SNG is a paradigm shift in anti-viral scientific thinking. It needs publicised as much as possible.

This appears to be a summary of relevant data, publications and the odd opinion to date.
Of interest the first reference is to P Monks forthcoming presentation in May which neatly summarises the evidence to date.

https://twitter.com/rickabright/status/1645546055180722180?s=46&t=lUUs8mZ3DzN0LONpU_7P4w
It took 2 years but with funding now unlocked SNGs future could be bright (forgive the pun)